Cochrane · systematic review · CD010268
Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) related complications in surgical patients
Gurusamy, KS, Koti, R, Wilson, P, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
WoundsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
38
current version
GRADE rated
38
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 36 · 94.7%Low 2 · 5.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: mortality
Population: surgical patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer) | no estimate extracted | 1 study · 275 participants | Very low Downgraded: risk of bias |
Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases) | no estimate extracted | 1 study · 143 participants | Very low Downgraded: risk of bias |
Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy) | RR 0.54 [0.17, 1.72] | 1 study · 99 participants | Very low Downgraded: risk of bias |
Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease) | RR 2.02 [0.18, 22.18] | 1 study · 884 participants | Very low Downgraded: risk of bias |
Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: surgical site infection
Population: surgical patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cefamendole versus cefamendole and gentamycin (median sternotomy) | RR 5.08 [0.24, 105.24] | 1 study · 522 participants | Very low Downgraded: risk of bias |
Cefazolin versus cefamendole (median sternotomy) | RR 3.55 [0.75, 16.95] | 1 study · 514 participants | Very low Downgraded: risk of bias |
Cefazolin versus cefazolin and gentamycin (median sternotomy) | RR 0.87 [0.32, 2.36] | 1 study · 508 participants | Very low Downgraded: risk of bias |
Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy) | RR 0.26 [0.11, 0.65] | 1 study · 99 participants | Low Downgraded: risk of bias |
Daptomycin and cefazolin versus cefazolin (vascular surgery) | RR 0.3 [0.07, 1.37] | 1 study · 113 participants | Very low Downgraded: risk of bias |
Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases) | RR 0.46 [0.21, 1.01] | 1 study · 143 participants | Very low Downgraded: risk of bias |
Levofloxacin versus ofloxacin (breast cancer) | RR 0.66 [0.18, 2.39] | 1 study · 181 participants | Very low Downgraded: risk of bias |
One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam (elective colorectal surgery) | RR 1.06 [0.52, 2.15] | 1 study · 521 participants | Very low Downgraded: risk of bias |
One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer) | RR 0.79 [0.3, 2.07] | 1 study · 275 participants | Very low Downgraded: risk of bias |
Pefloxacin versus cefazolin and oxacillin (tibial fracture requiring external fixation) | RR 0.74 [0.43, 1.28] | 1 study · 616 participants | Very low Downgraded: risk of bias |
Vancomycin and cefazolin versus cefazolin (open fractures) | RR 1 [0.27, 3.76] | 1 study · 92 participants | Very low Downgraded: risk of bias |
Vancomycin and cefazolin versus cefazolin (vascular surgery) ‐ suggest add for all comparisons | RR 0.97 [0.38, 2.5] | 1 study · 118 participants | Very low Downgraded: risk of bias |
Vancomycin and cefazolin versus daptomycin and cefazolin (vascular surgery) | RR 3.19 [0.69, 14.65] | 1 study · 107 participants | Very low Downgraded: risk of bias |
Vancomycin versus teicoplanin (paediatric cardiac surgery) | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias |
Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease) | RR 1.08 [0.53, 2.21] | 1 study · 884 participants | Very low Downgraded: risk of bias |
Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: MRSA surgical site infection
Population: surgical patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cefamendole versus cefamendole and gentamycin (median sternotomy) | no estimate extracted | 1 study · 522 participants | Very low Downgraded: risk of bias |
Cefazolin and gentamycin versus cefamendole and gentamycin (median sternotomy) | no estimate extracted | 1 study · 516 participants | Very low Downgraded: risk of bias |
Cefazolin versus cefamendole (median sternotomy) | RR 3.05 [0.12, 74.45] | 1 study · 514 participants | Very low Downgraded: risk of bias |
Cefazolin versus cefazolin and gentamycin (median sternotomy) | RR 2.98 [0.12, 72.72] | 1 study · 508 participants | Very low Downgraded: risk of bias |
Co‐amoxiclav or cefotaxime versus placebo (percutaneous endoscopic gastrostomy) | RR 0.05 [0, 0.83] | 1 study · 99 participants | Low Downgraded: risk of bias |
Daptomycin and cefazolin versus cefazolin (vascular surgery) | RR 0.24 [0.01, 4.94] | 1 study · 113 participants | Very low Downgraded: risk of bias |
Ertapenem versus cefotetan (elective colorectal surgery) | RR 0.59 [0.14, 2.46] | 1 study · 672 participants | Very low Downgraded: risk of bias |
Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases) | RR 1.97 [0.37, 10.43] | 1 study · 143 participants | Very low Downgraded: risk of bias |
Levofloxacin versus ofloxacin (breast cancer) | no estimate extracted | 1 study · 181 participants | Very low Downgraded: risk of bias |
One day of piperacillin, cefazolin, cefmetazole, or cefotiam versus three days of piperacillin, cefazolin, cefmetazole, or cefotiam (elective colorectal surgery) | no estimate extracted | 1 study · 521 participants | Very low Downgraded: risk of bias |
One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer) | RR 1.02 [0.21, 4.98] | 1 study · 275 participants | Very low Downgraded: risk of bias |
Pefloxacin versus cefazolin and oxacillin (tibial fracture requiring external fixation) | RR 3.8 [0.43, 33.78] | 1 study · 616 participants | Very low Downgraded: risk of bias |
Vancomycin and cefazolin versus cefazolin (open fractures) | RR 3 [0.13, 71.78] | 1 study · 92 participants | Very low Downgraded: risk of bias |
Vancomycin and cefazolin versus cefazolin (vascular surgery) | RR 2.21 [0.42, 11.63] | 1 study · 118 participants | Very low Downgraded: risk of bias |
Vancomycin and cefazolin versus daptomycin and cefazolin (vascular surgery) | RR 8.21 [0.45, 148.84] | 1 study · 107 participants | Very low Downgraded: risk of bias |
Vancomycin versus teicoplanin (paediatric cardiac surgery) | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias |
Vancomycin versus cefuroxime (coronary artery bypass graft without valvular disease) | RR 1.01 [0.14, 7.13] | 1 study · 884 participants | Very low Downgraded: risk of bias |
Antibiotic prophylaxis for the prevention of methicillin‐resistant Staphylococcus aureus (MRSA) infections and related complications in surgical patients: overall MRSA infections
Population: surgical patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
One dose of cefotiam or cefmetazol versus four doses of cefotiam or cefmetazol (elective surgery for colon cancer) | RR 0.77 [0.17, 3.36] | 1 study · 275 participants | Very low Downgraded: risk of bias |
Kanamycin, erythromycin and cefotiam versus cefotiam (surgery for colorectal diseases) | RR 1.97 [0.62, 6.26] | 1 study · 143 participants | Very low Downgraded: risk of bias |